Pancreatic Cancer Vaccine Trial Found Immune Responses but Missed Its Main Goal
Elicio Therapeutics’ off-the-shelf pancreatic cancer vaccine, ELI-002 7P, achieved robust T-cell responses in 99% of patients in Phase 2 trial results.
Pancreatic Cancer Vaccine Trial Found Immune Responses but Missed Its Main Goal Read More